Nektar Therapeutics (NKTR) Construction in Progress (2010 - 2024)
Nektar Therapeutics (NKTR) posted quarterly Construction in Progress of $245000.0 for Q4 2024, down 66.85% year-over-year from $739000.0 in Q1 2024, and up 77.54% quarter-over-quarter from $138000.0 in Q3 2024.
Nektar Therapeutics (NKTR) Construction in Progress (2010 - 2024) Analysis & Trends
Nektar Therapeutics' Construction in Progress history runs 15 years deep, the most recent figure standing at $245000.0 for Q4 2024.
- In Q4 2024, Construction in Progress fell 66.85% year-over-year to $245000.0; the TTM figure through Dec 2024 stood at $245000.0 (down 66.85% YoY), while the FY2024 annual figure was $245000.0, down 66.85% from the prior year.
- Construction in Progress for Q4 2024 stood at $245000.0, up from $138000.0 in the prior quarter.
- The five-year high for Construction in Progress was $7.2 million in Q4 2021, with the low at $138000.0 in Q3 2024.
- The 5-year median for Construction in Progress is $731500.0 (2023), against an average of $1.8 million.
- Peak annual rise in Construction in Progress reached 57.05% in 2024, while the deepest fall reached 71.72% in 2024.
- Nektar Therapeutics' Construction in Progress stood at $4.7 million in 2020, then surged by 52.4% to $7.2 million in 2021, then tumbled by 64.68% to $2.5 million in 2022, then sank by 70.79% to $739000.0 in 2023, then sank by 66.85% to $245000.0 in 2024.
- Business Quant data shows NKTR's Construction in Progress at $245000.0 in Q4 2024, $138000.0 in Q3 2024, and $724000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 245,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Dec 31, 2023 | 739,000.00 |
| Sep 30, 2023 | 488,000.00 |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 811,000.00 |
| Dec 31, 2022 | 2.53 Mn |
| Dec 31, 2021 | 7.16 Mn |
| Dec 31, 2020 | 4.70 Mn |
| Dec 31, 2019 | 5.22 Mn |
| Dec 31, 2018 | 5.09 Mn |
| Dec 31, 2017 | 1.40 Mn |
| Dec 31, 2016 | 3.46 Mn |
| Dec 31, 2015 | 8.46 Mn |
| Dec 31, 2014 | 16.31 Mn |
| Dec 31, 2013 | 6.26 Mn |
| Dec 31, 2012 | 2.77 Mn |
| Dec 31, 2011 | 1.75 Mn |
| Dec 31, 2010 | 2.56 Mn |